Lilly Novo Nordisk Battle Intensifies as Obesity Drugs Surge
Eli Lilly's Q1 2026 results slam the lid on the GLP-1 duopoly's early calm, with Lilly’s revenue exploding and Novo N...
Review year-by-year annual performance for index funds to uncover patterns that inform proactive asset allocation.
25,727 articlesEli Lilly's Q1 2026 results slam the lid on the GLP-1 duopoly's early calm, with Lilly’s revenue exploding and Novo N...
Losing a spouse is hard, and navigating survivor benefits can feel overwhelming. This guide breaks down how survivor ...
Investors are watching canopy growth's medical marijuana as a potential engine for a rebound. This guide breaks down ...
Palantir CEO Alex Karp argues that token-based access to frontier AI models is eroding enterprise value. The remarks ...
After a harsh downturn, some signs point to resilience. This guide explains what investors should watch, practical st...
General Dynamics posted a strong first quarter, while Lockheed Martin unveiled a major Ultra Maritime purchase, sharp...
Interactive Brokers grew customer accounts by 34% in the last year, signaling strong momentum in a competitive discou...
Dive into how to read myriad genetics (mygn) 2025 earnings transcripts, spot growth drivers, assess risk, and build a...
General Mills is down 20% this year as executives double down on value promotions to win back budget-conscious shoppe...
Nebius surges on a pair of cloud deals and a swelling backlog, but a late Q4 miss and execution doubts keep investors...
Amazon plans to move Prime Day earlier this summer, aiming to boost Q2 results and reframe the competitive promo cale...
Insmed disclosed that Japan now hosts more MAC lung disease patients than the United States, a development that could...